Entero Healthcare Solutions Ltd (ENTERO) — share price & stock analysis
From losses in FY21 and FY22 and FY23 to record profits — the comeback is real, the price knows it.
Entero Healthcare Solutions Ltd (ENTERO) trades at ₹1,190 as of 1 July 2026, down 3.5% over the past year — beating NIFTY 500 for 3 weeks. The machine reads this as turnaround: from losses in FY21 and FY22 and FY23 to record profits — the comeback is real, the price knows it. the price is in Stage 2 — advancing, 9 weeks in; the business cycle reads DEEP CYCLICAL / EXPANSION. Fundamentals-momentum score: 74/100 (mostly improving).
Data as of 1 July 2026 · every number traces to its Screener source column · not investment advice.
- Market cap
- ₹5,177 Cr
- P/E
- 43.4×
- ROE
- 7.0%
- Book value / share
- ₹388
- Revenue (FY26)
- ₹6,591 Cr
- Profit after tax (FY26)
- ₹146 Cr
- Weinstein stage
- Stage 2 (9 weeks)
- Data as of
- 1 July 2026
Profits swing violently in this business — real losses in FY21 and FY22 and FY23. That is what “deep cyclical” means: the same company looks brilliant at the top of its cycle and broken at the bottom.net_profit
Where the clock stands now: earnings sit at 100% of their historical range, margins are the best ever printed, and valuation history is thin. That reads as EXPANSION — the comfortable middle — but the records are already on the table; from here the bet is that they keep coming.net_profit
3 of the 5 things we track are currently moving the right way — most of the dashboard is turning up.
Where the levels actually stand: ROCE 11% — weak; debt moderate (0.4× equity); margins at an all-time high. Momentum says which way things are moving; these say where they are.
Read this number for what it is: it measures the DIRECTION of change, not the quality of the business. A mediocre business getting better scores high here; a great one having a soft quarter scores low. Profit, sales and margins count double, and a quarter of the score comes from our earnings-recovery lens (is the profit cycle turning up off its trough?).
Stage 2: the trend is up, and has been for 9 weeks
STAGE 2 · ADVANCING · 9 WEEKSPrice trends have a life cycle: they base (1), advance (2), top out (3) and decline (4). This chart is in Stage 2: advancing — 9 weeks so far, confirmed.stage
The price sits above its rising 200-day average (₹1,162 today) — trends like this persist more often than they reverse, which is why the system rides them instead of guessing the top.dma_200
Beating NIFTY 500 for 3 weeks — relative strength is the market’s live opinion, and right now it is on this stock’s side.rs_mansfield
What would end it: two Friday closes in a row below the 200-day line. That is the house exit rule — mechanical, no debates.dma_200
Data: Weekly price, moving averages and stage (sampled — full series in the embedded dataset)
| Period | Price (₹) | 200-DMA (₹) | 50-DMA (₹) | Stage |
|---|---|---|---|---|
| Feb 24 | 1,150 | 1,150 | 1,150 | 4 |
| Mar 24 | 1,094 | 1,142 | 1,122 | 4 |
| Mar 24 | 988 | 1,127 | 1,078 | 4 |
| Apr 24 | 1,128 | 1,118 | 1,070 | 4 |
| May 24 | 1,047 | 1,118 | 1,091 | 4 |
| May 24 | 1,028 | 1,106 | 1,063 | 4 |
| Jun 24 | 1,041 | 1,097 | 1,052 | 4 |
| Jul 24 | 1,148 | 1,095 | 1,068 | 4 |
| Aug 24 | 1,245 | 1,106 | 1,117 | 4 |
| Aug 24 | 1,289 | 1,125 | 1,177 | 2 |
| Sep 24 | 1,432 | 1,162 | 1,275 | 2 |
| Oct 24 | 1,337 | 1,189 | 1,316 | 2 |
| Oct 24 | 1,354 | 1,211 | 1,332 | 2 |
| Nov 24 | 1,382 | 1,238 | 1,370 | 2 |
| Dec 24 | 1,457 | 1,254 | 1,366 | 2 |
| Dec 24 | 1,427 | 1,279 | 1,400 | 2 |
| Jan 25 | 1,293 | 1,295 | 1,396 | 2 |
| Feb 25 | 1,432 | 1,308 | 1,394 | 2 |
| Feb 25 | 1,265 | 1,305 | 1,346 | 2 |
| Mar 25 | 1,170 | 1,293 | 1,285 | 2 |
| Apr 25 | 1,161 | 1,275 | 1,230 | 4 |
| May 25 | 1,289 | 1,281 | 1,269 | 4 |
| May 25 | 1,427 | 1,299 | 1,335 | 4 |
| Jun 25 | 1,193 | 1,293 | 1,295 | 3 |
| Jul 25 | 1,233 | 1,274 | 1,231 | 3 |
| Jul 25 | 1,217 | 1,266 | 1,226 | 4 |
| Aug 25 | 1,206 | 1,265 | 1,238 | 4 |
| Sep 25 | 1,203 | 1,258 | 1,226 | 4 |
| Sep 25 | 1,083 | 1,242 | 1,185 | 4 |
| Oct 25 | 1,107 | 1,224 | 1,151 | 4 |
| Nov 25 | 1,089 | 1,209 | 1,129 | 4 |
| Nov 25 | 1,063 | 1,192 | 1,110 | 4 |
| Dec 25 | 965 | 1,167 | 1,064 | 4 |
| Jan 26 | 1,175 | 1,154 | 1,070 | 4 |
| Feb 26 | 1,155 | 1,155 | 1,107 | 4 |
| Feb 26 | 1,079 | 1,151 | 1,115 | 4 |
| Mar 26 | 1,013 | 1,136 | 1,081 | 4 |
| Apr 26 | 1,249 | 1,140 | 1,117 | 4 |
| Apr 26 | 1,250 | 1,152 | 1,168 | 4 |
| May 26 | 1,192 | 1,160 | 1,186 | 4 |
| Jun 26 | 1,140 | 1,167 | 1,199 | 2 |
| Jun 26 | 1,135 | 1,166 | 1,188 | 2 |
| Jun 26 | 1,089 | 1,162 | 1,170 | 2 |
| Jul 26 | 1,190 | 1,162 | 1,168 | 2 |
Losses, then a rebuild: profits are at an all-time high
Over 6 years, sales went from ₹1,350 Cr to ₹6,591 Cr (about 30% a year), and profit from ₹1.0 Cr to ₹146 Cr.revenuenet_profit
The books show real losses in FY21 and FY22 and FY23 (worst: ₹−29.0 Cr). Everything about today’s cheap-looking numbers must be read against that history — the recovery is what you are buying.net_profit
Data: Revenue by year
| Period | Revenue (₹ Cr) |
|---|---|
| FY20 | 1,350 |
| FY21 | 1,773 |
| FY22 | 2,522 |
| FY23 | 3,300 |
| FY24 | 3,922 |
| FY25 | 5,096 |
| FY26 | 6,591 |
Data: Profit by year
| Period | Profit after tax (₹ Cr) |
|---|---|
| FY20 | 1 |
| FY21 | -15 |
| FY22 | -29 |
| FY23 | -11 |
| FY24 | 40 |
| FY25 | 107 |
| FY26 | 146 |
Data: OPM % by year
| Period | OPM % (%) |
|---|---|
| FY20 | 1.7 |
| FY21 | 0.8 |
| FY22 | 1.0 |
| FY23 | 1.9 |
| FY24 | 2.9 |
| FY25 | 3.4 |
| FY26 | 4.0 |
Sales exploded 43% last quarter — growth every single quarter for over 2 years
Mar 26 sales were ₹1,910 Cr, up 43% on the same quarter last year.revenue
That makes 10 quarters of growth in a row — this is a trend, not a blip.revenue
Data: Quarterly sales
| Period | Revenue (₹ Cr) | YoY growth (%) |
|---|---|---|
| Jun 23 | 899 | – |
| Sep 23 | 996 | – |
| Dec 23 | 993 | – |
| Mar 24 | 1,034 | – |
| Jun 24 | 1,097 | 22.0 |
| Sep 24 | 1,301 | 30.6 |
| Dec 24 | 1,359 | 36.9 |
| Mar 25 | 1,339 | 29.5 |
| Jun 25 | 1,404 | 28.0 |
| Sep 25 | 1,571 | 20.8 |
| Dec 25 | 1,707 | 25.6 |
| Mar 26 | 1,910 | 42.6 |
Margins have been rebuilt — 0.8% in FY21 to 4.0% now
Of every ₹100 of sales, the company keeps ₹4.5 as operating profit (a year ago it kept ₹3.6).opm_pct
Zoom out and this is the page's quiet hero: annual operating margin bottomed at 0.8% in FY21 and has been rebuilt to 4.0% — that recovery, not sales alone, is what powers the profit growth elsewhere on this page.operating_profit
Data: Three margins, quarterly
| Period | Gross (%) | Operating (%) | Net (%) |
|---|---|---|---|
| Jun 23 | 8.8 | 2.9 | 0.7 |
| Sep 23 | 9.0 | 2.9 | 0.5 |
| Dec 23 | 9.1 | 2.9 | 0.7 |
| Mar 24 | 9.0 | 2.8 | 2.1 |
| Jun 24 | 9.1 | 2.8 | 1.9 |
| Sep 24 | 9.4 | 3.3 | 2.0 |
| Dec 24 | 9.8 | 3.7 | 2.2 |
| Mar 25 | 9.8 | 3.7 | 2.4 |
| Jun 25 | 9.9 | 3.6 | 2.2 |
| Sep 25 | 10.2 | 4.0 | 2.3 |
| Dec 25 | 10.1 | 4.0 | 2.3 |
| Mar 26 | 10.9 | 4.5 | 2.4 |
Profit exploded 45% — mostly from selling more
Mar 26 profit after tax was ₹45.0 Cr, up 45% year on year.net_profit
Data: Quarterly profit after tax
| Period | PAT (₹ Cr) | YoY growth (%) |
|---|---|---|
| Jun 23 | 6.0 | – |
| Sep 23 | 5.0 | – |
| Dec 23 | 7.0 | – |
| Mar 24 | 21.0 | – |
| Jun 24 | 21.0 | 250.0 |
| Sep 24 | 26.0 | 420.0 |
| Dec 24 | 29.0 | 314.3 |
| Mar 25 | 31.0 | 47.6 |
| Jun 25 | 30.0 | 42.9 |
| Sep 25 | 37.0 | 42.3 |
| Dec 25 | 34.0 | 17.2 |
| Mar 26 | 45.0 | 45.2 |
The single biggest driver was selling more.
Data: Where the profit change came from (Mar 25 → Mar 26)
| Component | Effect (₹ Cr) |
|---|---|
| PAT Mar 25 | 31 |
| More sales | +21 |
| Fatter margins | +16 |
| Other income | −3 |
| Depreciation | −7 |
| Interest | −7 |
| Tax | −7 |
| Everything else | +1 |
| PAT Mar 26 | 45 |
Profits on paper, cash lagging behind
Over the last 3 profitable years, the business reported ₹293 Cr of profit and collected ₹−18.0 Cr of operating cash — about -6% conversion (2 loss years excluded — a negative denominator would flatter the ratio).operating_cash_flownet_profit
The wrinkle is the latest year: FY26 collected ₹96.0 Cr against ₹146 Cr of reported profit — about 66%. One year isn’t a trend, but it is the line to watch.operating_cash_flownet_profit
The gap sits in receivables: customers now take 67 days to pay, up from 59. Profit booked, cash pending.debtor_days
Data: Cash collected vs profit reported (annual)
| Period | Operating cash flow (₹ Cr) | Profit after tax (₹ Cr) |
|---|---|---|
| FY20 | -37.0 | 1.0 |
| FY21 | -69.0 | -15.0 |
| FY22 | -35.0 | -29.0 |
| FY23 | -45.0 | -11.0 |
| FY24 | -37.0 | 40.0 |
| FY25 | -77.0 | 107 |
| FY26 | 96.0 | 146 |
The cash cycle is stable
One rupee now takes about 74 days to go out the door as materials and come back as collected cash — down from 80 days the year before.cash_conversion_cycle
The biggest mover: suppliers being paid later (31 → 45 days).payable_days
Data: Days of cash locked up (annual)
| Period | Customers owe (debtor days) (days) | Stock on shelf (inventory days) (days) | We owe suppliers (payable days) (days) |
|---|---|---|---|
| FY20 | 63.0 | 57.0 | 32.0 |
| FY21 | 50.0 | 54.0 | 22.0 |
| FY22 | 54.0 | 49.0 | 22.0 |
| FY23 | 57.0 | 41.0 | 25.0 |
| FY24 | 57.0 | 43.0 | 24.0 |
| FY25 | 59.0 | 52.0 | 31.0 |
| FY26 | 67.0 | 52.0 | 45.0 |
The asset base keeps compounding — this company builds
The productive asset base has gone from ₹186 Cr (FY20) to ₹960 Cr.fixed_assetscwip
The build is bigger than the cash engine: investing outflows (₹775 Cr) exceeded operating cash (₹−18.0 Cr) over the last 3 years — the difference comes from debt or shareholders.investing_cash_flowoperating_cash_flow
Data: Assets in place vs under construction (annual)
| Period | Fixed assets (₹ Cr) | Under construction (CWIP) (₹ Cr) |
|---|---|---|
| FY20 | 186 | 2.0 |
| FY21 | 189 | 2.0 |
| FY22 | 262 | 1.0 |
| FY23 | 268 | 0.0 |
| FY24 | 289 | 0.0 |
| FY25 | 559 | 0.0 |
| FY26 | 960 | 0.0 |
Debt is present but comfortable
For every ₹100 shareholders have put in (and left in), the company has borrowed ₹40.borrowings
Data: Total borrowings (annual)
| Period | Borrowings (₹ Cr) |
|---|---|
| FY20 | 603 |
| FY21 | 720 |
| FY22 | 974 |
| FY23 | 1,101 |
| FY24 | 338 |
| FY25 | 385 |
| FY26 | 677 |
Data: Debt vs shareholders’ money (annual)
| Period | Debt ÷ equity (x) |
|---|---|
| FY20 | -37.9 |
| FY21 | -22.6 |
| FY22 | -16.8 |
| FY23 | -16.0 |
| FY24 | 0.2 |
| FY25 | 0.2 |
| FY26 | 0.4 |
Every ₹100 kept in the business earns just ₹11
Return on capital employed is 11.0% (a year ago: 9.0%). This is the single best test of business quality: what the company earns on the money it keeps.roce_pct
Data: Returns on capital (annual)
| Period | ROCE (%) |
|---|---|
| FY21 | 1.0 |
| FY22 | 1.0 |
| FY23 | 5.0 |
| FY24 | 7.0 |
| FY25 | 9.0 |
| FY26 | 11.0 |
Institutions have been lightening up
Promoters hold 52.4%, essentially unchanged. Foreign funds own 4.0%, domestic funds 16.6%.promoters_pctfiis_pctdiis_pct
Institutions buying while the story develops is the market’s quiet vote of confidence — they meet management, you don’t.
Meanwhile foreign funds have been the sellers — from 23.3% to 4.0% over the window. Someone on the other side of the table disagrees; both sides count.fiis_pct
Data: Who holds the shares, quarterly
| Period | Promoters (%) | Foreign funds (%) | Domestic funds (%) |
|---|---|---|---|
| Mar 24 | 52.4 | 23.3 | 2.3 |
| Jun 24 | 52.4 | 23.3 | 2.1 |
| Sep 24 | 52.4 | 23.8 | 7.7 |
| Dec 24 | 52.4 | 22.2 | 8.8 |
| Mar 25 | 52.4 | 19.9 | 9.6 |
| Jun 25 | 52.4 | 17.2 | 10.2 |
| Sep 25 | 52.4 | 14.7 | 9.6 |
| Dec 25 | 52.4 | 5.1 | 16.4 |
| Mar 26 | 52.4 | 4.0 | 16.6 |
- Promoters are not selling. Their stake has moved 0.1 points or less in 8 quarters — it sits at 52.4%.promoters_pct
- Margins are not the story. Operating margin has stayed in a 2.8–4.5% band for two years — whatever moves this stock, it isn’t profitability per rupee of sales.opm_pct
Strong on the data — worth the deeper look if the story keeps its promises
The numbers lean positive, and the price is roughly fair to the delivery so far.
Best thing in the data: cash generation rising (₹−77.0 Cr → ₹96.0 Cr).operating_cash_flow
Biggest worry: free cash flow falling (₹155 Cr → ₹−207 Cr).operating_cash_flow
Machine-written research from Screener data — every number traces to its source column. Sector Alpha is not a SEBI-registered investment adviser; nothing here is a recommendation to buy or sell. Not investment advice.
Straight answers from the data
What does Entero Healthcare Solutions Ltd do?
Incorporated in 2018, Entero Healthcare Solutions Ltd is in the business of distribution and marketing of pharmaceutical and surgical products and allied services[1]. It is listed in the Pharmacy Distribution sector with a market capitalisation of ₹5,177 Cr.
What is Entero Healthcare Solutions Ltd's share price?
As of 1 July 2026, Entero Healthcare Solutions Ltd trades at ₹1,190, down 3.5% over the past year, with a market capitalisation of ₹5,177 Cr. Beating NIFTY 500 for 3 weeks. Prices are weekly closes from Screener data; this page refreshes with each weekly update.
What is Entero Healthcare Solutions Ltd's share price target?
Sector Alpha does not publish broker-style price targets. Our discounted-cash-flow model estimates Entero Healthcare Solutions Ltd's intrinsic value at ₹982 per share under base assumptions (bear ₹324, bull ₹982), against the current price of ₹1,190 — a 17% premium to model value. The current price already implies roughly 22% annual earnings growth. These are model estimates, not forecasts — treat them as one input alongside the valuation history below, not as a target.
What did Entero Healthcare Solutions Ltd report in its latest quarterly results?
In its most recent reported quarter (Q4 FY26, quarter ended March 2026): Mar 26 sales were ₹1,910 Cr, up 43% on the same quarter last year. Mar 26 profit after tax was ₹45.0 Cr, up 45% year on year. Figures are from Screener-scraped quarterly filings; the page updates when the next quarter is filed.
Is Entero Healthcare Solutions Ltd growing?
Sales exploded 43% last quarter — growth every single quarter for over 2 years. Mar 26 sales were ₹1,910 Cr, up 43% on the same quarter last year.
Are Entero Healthcare Solutions Ltd's profits growing?
Profit exploded 45% — mostly from selling more. Mar 26 profit after tax was ₹45.0 Cr, up 45% year on year.
What are Entero Healthcare Solutions Ltd's operating margins?
Margins have been rebuilt — 0.8% in FY21 to 4.0% now. In the most recent quarter, of every ₹100 of sales, the company keeps ₹4.5 as operating profit (a year ago it kept ₹3.6).
What is Entero Healthcare Solutions Ltd's long-term growth record?
Revenue grew from ₹1,350 Cr in FY20 to ₹6,591 Cr in FY26 — a 30.2% compound annual growth rate over 6 years. Profit after tax compounded at 129.5% over the same period (₹1 Cr → ₹146 Cr).
Is Entero Healthcare Solutions Ltd stock in an uptrend?
Stage 2: the trend is up, and has been for 9 weeks. Entero Healthcare Solutions Ltd is in Stage 2 — advancing, 9 weeks in (confirmed). Stages follow Stan Weinstein's four-phase read of weekly price against the 200-day average: basing (1), advancing (2), topping (3), declining (4).
Is Entero Healthcare Solutions Ltd beating the NIFTY 500?
Yes — beating NIFTY 500 for 3 weeks, as of 1 July 2026. Relative strength is measured weekly against the NIFTY 500 (Mansfield RS): a positive reading means the stock has outperformed the index over the trailing window, week after week.
Where is Entero Healthcare Solutions Ltd in its business cycle?
The data reads Entero Healthcare Solutions Ltd as a deep cyclical business currently in its expansion phase — earnings at an all-time high for this company. Profits swing violently in this business — real losses in FY21 and FY22 and FY23. That is what “deep cyclical” means: the same company looks brilliant at the top of its cycle and broken at the bottom.
Who owns Entero Healthcare Solutions Ltd — what is the promoter holding?
Promoters hold 52.4%, essentially unchanged. Foreign funds own 4.0%, domestic funds 16.6%. Institutions buying while the story develops is the market’s quiet vote of confidence — they meet management, you don’t. Shareholding is from Screener's quarterly filings data.
Does Entero Healthcare Solutions Ltd have too much debt?
Debt is present but comfortable. For every ₹100 shareholders have put in (and left in), the company has borrowed ₹40.
What is the bull case for Entero Healthcare Solutions Ltd?
From losses in FY21 and FY22 and FY23 to record profits — the comeback is real, the price knows it. Best thing in the data: cash generation rising (₹−77.0 Cr → ₹96.0 Cr). Sales exploded 43% last quarter — growth every single quarter for over 2 years.
What is the bear case for Entero Healthcare Solutions Ltd — what could break the story?
Biggest worry: free cash flow falling (₹155 Cr → ₹−207 Cr). Two quarters of profit reversing would kill this story. The nearest-term thing to watch: if quarterly growth slips below 21%, the story weakens. This falsification condition is stated up front so the thesis can be checked against incoming quarters, not defended after the fact.
Is Entero Healthcare Solutions Ltd a stock worth studying right now?
Sector Alpha does not publish buy or sell recommendations — this is a research read, not advice. What the data says: strong on the data — worth the deeper look if the story keeps its promises. The numbers lean positive, and the price is roughly fair to the delivery so far. Across the 7-model scorecard the composite research signal is study deeper at 73% confidence. This is machine-written research compiled from Screener data — every number traces to its source — and it is not investment advice. Do your own diligence.